| 0.7015 0.026 (3.88%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.92 |
1-year : | 1.07 |
| Resists | First : | 0.79 |
Second : | 0.92 |
| Pivot price | 0.62 |
|||
| Supports | First : | 0.65 |
Second : | 0.57 |
| MAs | MA(5) : | 0.63 |
MA(20) : | 0.63 |
| MA(100) : | 0.82 |
MA(250) : | 0.75 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 53.9 |
D(3) : | 38.2 |
| RSI | RSI(14): 57.2 |
|||
| 52-week | High : | 1.75 | Low : | 0.47 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LGVN ] has closed Bollinger Bands are 60.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.77 - 0.77 | 0.77 - 0.77 |
| Low: | 0.68 - 0.68 | 0.68 - 0.68 |
| Close: | 0.7 - 0.7 | 0.7 - 0.71 |
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Sat, 01 Aug 2026
Longeveron Inc (LGVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fri, 31 Jul 2026
Longeveron Inc (LGVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Wed, 29 Jul 2026
Longeveron (NASDAQ: LGVN) refreshes audit committee with four independent directors - Stock Titan
Wed, 29 Jul 2026
Longeveron Inc (LGVN) Institutional Confidence - TradingKey
Tue, 28 Jul 2026
Longeveron Inc. Revenue Breakdown – NASDAQ:LGVN - TradingView
Sat, 25 Jul 2026
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 2.586e+007 (%) |
| Held by Institutions | 9.3 (%) |
| Shares Short | 1,830 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.162e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 149.5 % |
| Return on Equity (ttm) | -67.5 % |
| Qtrly Rev. Growth | 1.22e+006 % |
| Gross Profit (p.s.) | -141.08 |
| Sales Per Share | -588.4 |
| EBITDA (p.s.) | 2.86786e+006 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -0.49 |
| Dividend | 0 |
| Forward Dividend | 1.53e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|